Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s646, 2025. DOI: 10.25251/ta5v8k92. Disponível em: https://skin.dermsquared.com/skin/article/view/3869. Acesso em: 18 apr. 2026.